We are live on ! Find out more
KALA icon

KALA BIO

99 hedge funds and large institutions have $79.4M invested in KALA BIO in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

17% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 23

2% more funds holding

Funds holding: 9799 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% less ownership

Funds ownership: 0.02%0.02% (-0%)

54% less capital invested

Capital invested by funds: $171M → $79.4M (-$91.6M)

57% less call options, than puts

Call options by funds: $388K | Put options by funds: $907K

Holders
99
Holders Change
+2
Holders Change %
+2.06%
% of All Funds
1.73%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
27
Reduced
23
Closed
13
Calls
$388K
Puts
$907K
Net Calls
-$519K
Net Calls Change
-$1.5M

KALA Hedge Fund Activity: Q3 2021 in Review

99 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q3 2021, worth a combined $79.4M — down 54% from $171M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new KALA positions and 13 closed out — a net gain of 3 holders — while 27 added to existing stakes and 23 trimmed.

The largest buyer was State Street, adding an estimated $1M. The largest seller was OrbiMed, cutting an estimated $7M.

  • 99 institutional investors held KALA BIO (KALA) as of Q3 2021, up from 97 in Q2 2021.
  • Funds reported $79.4M of KALA BIO stock for Q3 2021, down 54% quarter-over-quarter.
  • 16 funds opened new KALA BIO positions in Q3 2021 and 13 closed out, a net change of +3 holders.
  • The largest KALA BIO buyer in Q3 2021 was State Street, an estimated $1M added.
  • The largest KALA BIO seller in Q3 2021 was OrbiMed, an estimated $7M sold.

Based on aggregated 13F filings for Q3 2021.